{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1383670319224919680.json","@type":"Researcher","foaf:Person":[{"foaf:name":[{"@value":"M. A. Bookman"}],"foaf:familyName":[{"@value":"Bookman"}],"foaf:givenName":[{"@value":"M. A."}]}],"career":[{"institution":{"notation":[{"@value":"Fox Chase Cancer Center, Philadelphia, PA"}]}}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1363670319224919680","@type":"Article","productIdentifier":[{"@type":"DOI","@value":"10.1200/jco.2006.24.18_suppl.5002"}],"notation":[{"@value":"GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma"}],"relation":[{"type":"creator"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1200/jco.2006.24.18_suppl.5002_6YRNgBGwkmWgPDb82uTi0oY8Srq"}]}